EdgarLookup

Doximity, Inc. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that Doximity, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
39.1%
Profit Margin
Net income ÷ revenue
17.7%
Return on Assets
Net income ÷ assets
0.17x
Debt-to-Equity
Total liabilities ÷ equity
+20%
Revenue Growth
Year over year

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $570.40M May 20, 2025
FY2025 Mar 31, 2024 $475.42M May 20, 2025
FY2025 Mar 31, 2023 $419.05M May 20, 2025
FY2024 Mar 31, 2022 $343.55M May 23, 2024
FY2023 Mar 31, 2021 $206.90M May 26, 2023
FY2022 Mar 31, 2020 $116.39M May 27, 2022

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $514.53M May 20, 2025
FY2025 Mar 31, 2024 $424.75M May 20, 2025
FY2025 Mar 31, 2023 $365.56M May 20, 2025
FY2024 Mar 31, 2022 $303.76M May 23, 2024
FY2023 Mar 31, 2021 $175.70M May 26, 2023
FY2022 Mar 31, 2020 $101.49M May 27, 2022

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $223.19M May 20, 2025
FY2025 Mar 31, 2024 $147.58M May 20, 2025
FY2025 Mar 31, 2023 $112.82M May 20, 2025
FY2024 Mar 31, 2022 $154.78M May 23, 2024
FY2023 Mar 31, 2021 $50.21M May 26, 2023
FY2022 Mar 31, 2020 $29.74M May 27, 2022

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $227.80M May 20, 2025
FY2025 Mar 31, 2024 $163.88M May 20, 2025
FY2025 Mar 31, 2023 $125.11M May 20, 2025
FY2024 Mar 31, 2022 $113.54M May 23, 2024
FY2023 Mar 31, 2021 $53.30M May 26, 2023
FY2022 Mar 31, 2020 $22.16M May 27, 2022

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $93.04M May 20, 2025
FY2025 Mar 31, 2024 $81.98M May 20, 2025
FY2025 Mar 31, 2023 $80.19M May 20, 2025
FY2024 Mar 31, 2022 $62.35M May 23, 2024
FY2023 Mar 31, 2021 $43.87M May 26, 2023
FY2022 Mar 31, 2020 $32.44M May 27, 2022

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $273.27M May 20, 2025
FY2025 Mar 31, 2024 $184.10M May 20, 2025
FY2025 Mar 31, 2023 $179.60M May 20, 2025
FY2024 Mar 31, 2022 $126.58M May 23, 2024
FY2023 Mar 31, 2021 $82.97M May 26, 2023
FY2022 Mar 31, 2020 $26.20M May 27, 2022

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $0 May 20, 2025
FY2025 Mar 31, 2024 $147.0K May 20, 2025
FY2025 Mar 31, 2023 $1.70M May 20, 2025
FY2024 Mar 31, 2022 $1.91M May 23, 2024
FY2023 Mar 31, 2021 $245.0K May 26, 2023
FY2022 Mar 31, 2020 $285.0K May 27, 2022

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $1.26B May 20, 2025
FY2025 Mar 31, 2024 $1.08B May 20, 2025
FY2024 Mar 31, 2023 $1.14B May 23, 2024
FY2023 Mar 31, 2022 $991.36M May 26, 2023
FY2022 Mar 31, 2021 $251.72M May 27, 2022

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $181.68M May 20, 2025
FY2025 Mar 31, 2024 $177.98M May 20, 2025
FY2024 Mar 31, 2023 $170.77M May 23, 2024
FY2023 Mar 31, 2022 $112.76M May 26, 2023
FY2022 Mar 31, 2021 $103.52M May 27, 2022

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $1.08B May 20, 2025
FY2025 Mar 31, 2024 $901.40M May 20, 2025
FY2025 Mar 31, 2023 $966.12M May 20, 2025
FY2025 Mar 31, 2022 $878.59M May 20, 2025
FY2024 Mar 31, 2021 $66.74M May 23, 2024
FY2023 Mar 31, 2020 $1.14M May 26, 2023
FY2022 Mar 31, 2019 ($32.94M) May 27, 2022

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $67.94M May 20, 2025
FY2025 Mar 31, 2024 $67.94M May 20, 2025
FY2024 Mar 31, 2023 $67.94M May 23, 2024
FY2024 Mar 31, 2022 $18.92M May 23, 2024
FY2022 Mar 31, 2021 $18.92M May 27, 2022

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $186.89M May 20, 2025
FY2025 Mar 31, 2024 $79.99M May 20, 2025
FY2024 Mar 31, 2023 $217.86M May 23, 2024
FY2023 Mar 31, 2022 $191.11M May 26, 2023
FY2022 Mar 31, 2021 $36.32M May 27, 2022

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 $209.61M May 20, 2025
FY2025 Mar 31, 2024 $96.79M May 20, 2025
FY2024 Mar 31, 2023 $158.03M May 23, 2024
FY2023 Mar 31, 2022 $112.81M May 26, 2023
FY2022 Mar 31, 2021 $66.39M May 27, 2022

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 1 May 20, 2025
FY2025 Mar 31, 2024 0 May 20, 2025
FY2025 Mar 31, 2023 0 May 20, 2025
FY2024 Mar 31, 2022 0 May 23, 2024
FY2023 Mar 31, 2021 0 May 26, 2023
FY2022 Mar 31, 2020 0 May 27, 2022

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 1 May 20, 2025
FY2025 Mar 31, 2024 0 May 20, 2025
FY2025 Mar 31, 2023 0 May 20, 2025
FY2024 Mar 31, 2022 0 May 23, 2024
FY2023 Mar 31, 2021 0 May 26, 2023
FY2022 Mar 31, 2020 0 May 27, 2022

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Mar 31, 2025 188.88M May 20, 2025
FY2025 Mar 31, 2024 186.56M May 20, 2025
FY2024 Mar 31, 2023 193.94M May 23, 2024
FY2023 Mar 31, 2022 192.40M May 26, 2023
FY2022 Mar 31, 2021 82.91M May 27, 2022